What Is Retatrutide?
Retatrutide (LY3437943) is an investigational peptide developed by Eli Lilly — the same company behind tirzepatide (Mounjaro, Zepbound). Where tirzepatide targets two receptors — GLP-1 and GIP — retatrutide adds a third: the glucagon receptor. This makes it a GLP-1/GIP/glucagon triple agonist, and that additional mechanism appears to produce meaningfully greater weight loss than either of its predecessors.
It is currently in Phase 3 clinical trials. It is not yet FDA-approved. But it is generating significant attention in the metabolic medicine space — both for its trial results and for what it suggests about the direction of next-generation GLP-1 therapy.
The Three Receptors — and Why It Matters
To understand why retatrutide is different, you need to understand what each receptor does and what activating all three simultaneously achieves.
GLP-1 (Glucagon-Like Peptide-1): The primary mechanism behind semaglutide and tirzepatide. Activating GLP-1 receptors stimulates insulin secretion, suppresses glucagon release, slows gastric emptying, and reduces appetite through signaling in the hypothalamus. This is responsible for most of the satiety and blood sugar regulation effects.
GIP (Glucose-Dependent Insulinotropic Polypeptide): Added by tirzepatide. GIP receptor activation amplifies the insulin response, improves fat metabolism, and appears to enhance the tolerability of GLP-1 agonism — meaning fewer GI side effects at higher doses.
Glucagon: The addition that makes retatrutide distinct. Glucagon receptor activation increases energy expenditure — the rate at which your body burns calories at rest. It also promotes fat breakdown in the liver, making retatrutide potentially useful for non-alcoholic fatty liver disease (NAFLD) in addition to obesity.
"Activating the glucagon receptor is counterintuitive — glucagon raises blood sugar. But at the doses used in retatrutide, the GLP-1 component offsets that effect while the glucagon receptor drives significantly greater fat oxidation."
How Does Retatrutide Compare to Semaglutide and Tirzepatide?
| Factor | Semaglutide | Tirzepatide | Retatrutide |
|---|---|---|---|
| Receptors Targeted | GLP-1 | GLP-1 + GIP | GLP-1 + GIP + Glucagon |
| Avg. Weight Loss (Trial) | ~15% | ~20% | ~24% |
| FDA Approval Status | Approved | Approved | Phase 3 trials |
| Energy Expenditure Effect | Moderate | Moderate | Enhanced (glucagon) |
| Liver Fat Reduction | Some | Significant | Potentially greater |
| Compounded Access (US) | Yes (503B) | Limited | Not yet available |
What the Phase 2 Trial Showed
The Phase 2 data published in the New England Journal of Medicine in 2023 enrolled 338 adults with obesity. Participants on the highest dose of retatrutide (12mg weekly) lost an average of 24.2% of their body weight over 48 weeks. Some participants lost more than 30% of body weight — results that approach those seen with bariatric surgery.
The trial also showed meaningful reductions in waist circumference, blood pressure, triglycerides, and fasting glucose. Liver fat reduction was observed across all dose groups.
Side effects were consistent with the GLP-1 class — primarily nausea, vomiting, and diarrhea, most commonly during dose escalation. No new safety signals emerged that were not already associated with existing GLP-1 therapies.
When Will Retatrutide Be Available?
Retatrutide is currently in Phase 3 trials under Eli Lilly. Phase 3 trials typically run 2 to 3 years, followed by FDA review. A realistic timeline for approval — if trials continue to be successful — is 2026 to 2027. Commercial availability and compounding access would follow approval.
This means that for patients who want access to the leading edge of GLP-1 therapy today, tirzepatide and compounded semaglutide remain the clinically available options. Both have demonstrated significant efficacy and are accessible through physician-supervised telehealth.
Physician-supervised GLP-1 therapy.
Semaglutide and tirzepatide, 503B cGMP sourced.
Why This Matters for Peptide Medicine
Retatrutide is significant beyond its own trial results. It represents a broader trajectory in GLP-1 development: the progression from single-receptor agonism toward increasingly precise multi-receptor targeting. Each generation has demonstrated meaningfully better outcomes than the last — and the research pipeline suggests this progression continues.
For patients who have not responded adequately to semaglutide, or who want to optimize beyond current options, monitoring the retatrutide approval timeline is worthwhile. For patients beginning a GLP-1 protocol today, compounded semaglutide and tirzepatide remain the evidence-backed standard — and with physician oversight, protocols can be adjusted as new options become available.
The most important factor is not which molecule you start with. It is starting with proper clinical oversight, verified sourcing, and a titration protocol designed around your specific physiology.